Volume : 12, Issue : 10, October – 2025
Title:
ASSESS THE ADVERSE DRUG REACTIONS OF VARIOUS COVID VACCINES
Authors :
Baddem Bhargavi, M.Madhavi Kumara, Dr.M.B.V.Raju
Abstract :
Background: Adverse drug reactions (ADRs) following COVID-19 vaccination have been reported globally, but data on their incidence, severity, and associated risk factors remain limited. This study aimed to evaluate the occurrence and characteristics of ADRs among recipients of Covaxin and Covishield vaccines.
Methods: A total of 372 participants were enrolled. ADRs were assessed in relation to age, gender, concomitant medications, and clinical manifestations. Causality and severity were evaluated using the WHO-UMC scale and the modified Hartwig and Siegel scale, respectively.
Results: Among participants, 62 receiving Covaxin and 267 receiving Covishield experienced ADRs. The majority occurred in the 45–59 years age group (33.77%) and predominantly in males (Covaxin 60.94%, Covishield 71%). Participants on antihypertensive therapy reported the highest incidence of ADRs (43.33%), followed by proton pump inhibitors (15.5%) and hormonal drugs (12.5%). The most common ADRs included severe pain at the injection site (90.8%), weakness (87.54%), fever (87.21%), fatigue (61.9%), joint pain (57.3%), and muscle ache (54.75%). Organ systems most frequently affected were the skin and musculoskeletal system (25.87%) and gastrointestinal system (23.24%). Causality assessment revealed 20.38% probable, 37.54% possible, and 34.62% certain ADRs. According to the modified Hartwig and Siegel scale, 49.25% of ADRs were mild.
Conclusion: ADRs following COVID-19 vaccination were common, particularly among middle-aged males and those on antihypertensive therapy. Most ADRs were mild and involved the musculoskeletal and skin systems. These findings highlight the importance of monitoring ADRs and providing guidance for vaccine recipients to manage expected side effects effectively.
Keywords: Adverse drug reactions, COVID-19 vaccination, Covaxin, Covishield
Cite This Article:
Please cite this article in press Baddem Bhargavi et al., Assess The Adverse Drug Reactions Of Various Covid Vaccines, Indo Am. J. P. Sci, 2025; 12(10).
REFERENCES:
1. E. Ammirati, M. Frigerio, E.D. Adler, C. Basso, D.H. Birnie, M. Brambatti, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document Fail, 13 (11) (2020), 10.1161/CIRCHEARTFAILURE.120.007405 Google Scholar
2. S. Abu Mouch, A. Roguin, E. Hellou, A. Ishai, U. Shoshan, L. Mahamid, et al. Myocarditis following COVID-19 mRNA vaccination Vaccine, 39 (29) (2021), pp. 3790-3793, 10.1016/j.vaccine.2021.05.087 ArticleDownloadPDFView Record in ScopusGoogle Scholar [3]S.A. Huber, B. Pfaeffle
3. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with Coxsackievirus group B type 3 J Virol, 68 (8) (1994), pp. 5126-5132 CrossRefView Record in ScopusGoogle Scholar
4. U. Sahin, K. Karikó, Ö. Türeci mRNA-based therapeutics – developing a new class of drugs Nat Rev Drug Discov, 13 (10) (2014), pp. 759-780, 10.1038/nrd4278 CrossRefView Record in ScopusGoogle Scholar
5. Astier, A. Barton Pai, M. Bissig, D.J.A. Crommelin, B. Flühmann, J.D. Hecq, et al. How to select a nanosimilar nn N Y Acad Sci, 1407 (1) (2017), pp. 50-62, 10.1111/nyas.13382 CrossRefView Record in ScopusGoogle Scholar
6. S. Tinari The EMA covid-19 data leak, and what it tells us about mRNA instability BMJ, 372 (2021), Article n627, 10.1136/bmj.n627 CrossRefView Record in ScopusGoogleScholarc
7. J Montgomery, M Ryan, R Engler, D Hoffman, B McClenathan, L Collins, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military JAMA Cardiol (2021), 10.1001/jamacardio.2021.2833 Google Scholar
8. J Nelson, EW Sorensen, S Mintri, AE Rabideau, W Zheng, G Besin, et al.Impact of mRNA chemistry and manufacturing process on innate immune activation Sci Adv, 6 (26) (2020), p. eaaz6893, 10.1126/sciadv.aaz6893 CrossRefView Record in ScopusGoogle Scholar
9. S. Mitra, The implications of COVID-19 for rural India, IDR 25 (2020). March, https ://idronline.org/the-implications-of-covid-19-for-rural-india/. [
10. Statistics Division, Ministry of Health & Family Welfare, Bulletin on rural health statistics in India.